Fluidigm Granted FDA Emergency Use Authorization for Saliva-Based Advanta Dx SARS-CoV-2 RT-PCR Assay for COVID-19
August 25, 2020 23:00 ET
|
Fluidigm Corporation
Easy-to-Administer Saliva Test for COVID-19 Available for Immediate Shipment Extraction-Free, Real-Time PCR Workflow with Capacity of up to 6,000 Tests per Day per System Demonstrated 100 Percent...
Fluidigm Announces Second Quarter 2020 Financial Results
August 06, 2020 16:05 ET
|
Fluidigm Corporation
Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based Test Multi-Site U.S. Study of COVID-19 Patients Utilizes Mass...
Fluidigm Announces Conference Call and Webcast of Second Quarter 2020 Financial Results
July 06, 2020 16:02 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm to Present at Upcoming Health Care Investor Conferences
May 13, 2020 16:02 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Announces First Quarter 2020 Financial Results
May 07, 2020 16:05 ET
|
Fluidigm Corporation
First Quarter Revenue Decreased 8 Percent to $27.6 Million New COVID-19 Opportunities for Microfluidics and Mass Cytometry Businesses Customers filing FDA Emergency Use Authorization for...
Cognition Therapeutics Announces Publication Analyzing Biomarkers of Synapse Damage or Loss to Support Future Therapeutic Development Efforts in Alzheimer's Disease
March 17, 2020 08:03 ET
|
Cognition Therapeutics, Inc.
New York, March 17, 2020 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical-stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s disease...
Fluidigm to Participate in Upcoming Investor Conferences
February 12, 2020 16:05 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Life Chiropractic College West uses biomarkers to support Vitalistic research
January 15, 2020 14:00 ET
|
Life Chiropractic College West
San Francisco Bay Area, California, Jan. 15, 2020 (GLOBE NEWSWIRE) -- How do we know – with irrefutable research and hard data – that someone who is living the chiropractic lifestyle is, in fact,...
Cognition Therapeutics to Present Findings from the Elayta™ Clinical Development Program at Society for Neuroscience Annual Meeting
October 10, 2019 08:02 ET
|
Cognition Therapeutics, Inc.
Pittsburgh, Oct. 10, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...
Cognition Therapeutics Receives $3.3 Million NIA Grant to Conduct qEEG Study of Elayta™ with World-Leading Alzheimer’s Biomarker Experts
July 09, 2019 08:02 ET
|
Cognition Therapeutics, Inc.
PITTSBURGH, July 09, 2019 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in Alzheimer’s...